<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905489</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1518</org_study_id>
    <secondary_id>2008-005855-61</secondary_id>
    <nct_id>NCT00905489</nct_id>
  </id_info>
  <brief_title>A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.</brief_title>
  <official_title>An Open-label, Multiple Dose, Cross-over Study to Evaluate the Steady-state Pharmacokinetic Parameters of Nevirapine Extended Release Tablets in HIV-1 Infected Children, With an Optional Extension Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective is to establish the pharmacokinetic (PK) profile at steady state of
      nevirapine XR in HIV infected children from &gt;=3 to &lt;18 years of age. This phase I trial is an
      open-label, multiple dose, non-randomized and cross-over study. Patients who have completed
      the last visit of the PK trial (visit 7) can enter into an Optional Extension Phase (OEP)
      until the Investigational New Drug (IND) is withdrawn; until nevirapine XR becomes approved
      and is available by prescription in a given country; or, the patient enrolls in a
      compassionate use program. During this OEP, nevirapine XR safety and efficacy information
      will be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Cpre,N.</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Trough Nevirapine concentration immediately prior to the next scheduled dose. Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.
The measure of dispersion presented is the coefficient of variation (%) rather than the geometric coefficient of variation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Area under the concentration-time curve of the Nevirapine (NVP) in plasma at steady state over the time dosing interval τ.
All patients received nevirapine IR for 10 days prior to collection of 12-hour Area Under the Curve (AUC) data. Then, all patients were switched to nevirapine XR for 9 days prior to collection of 24-hour AUC data. The treatments of IR and XR are summarized separately using geometric means and geometric coefficients of variation.
For NVP IR AUC measured over hours: 0,1,2,3,4,8 and 12, For NVP XR AUC measured over hours: 0,1,2,3,4,8,10,12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (for IR and XR Formulations by Nevirapine XR Dose Group)</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Minimum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ by nevirapine XR dose group Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (for IR and XR Formulations by Nevirapine XR Dose Group)</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Maximum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio Cmax,ss/Cmin,ss</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Ratio of (maximum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ)/(minimum measured concentration of the analyte in plasma at steady state over the time dosing interval τ) Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%PTF</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Percentage peak-trough Nevirapine fluctuation, % fluctuation (degree of peak to trough fluctuation) Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Time from dosing to the maximum concentration of the Nevirapine in plasma at steady state over the time dosing interval τ Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.
The standard deviation is actually the coefficient of variation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Apparent clearance of the Nevirapine in the plasma after extravascular administration at steady-state Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg</measure>
    <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
    <description>Average measured concentration of the Nevirapine in plasma at steady state Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL</measure>
    <time_frame>Day 22</time_frame>
    <description>Patients maintaining a viral load &lt; 50 copies/mL at Day 22.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Patients Maintaining a VL &lt; 400 Copies/mL</measure>
    <time_frame>Day 22</time_frame>
    <description>Patients maintaining a viral load &lt; 400 copies/mL at Day 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean CD4+ Count (Absolute)</measure>
    <time_frame>Baseline, Day 22 and week 24</time_frame>
    <description>Change in mean CD4+ count (absolute) from baseline to Day 22 and from baseline to Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Mean CD4+ Count</measure>
    <time_frame>Baseline to day 22 and baseline to week 24</time_frame>
    <description>((Day 22 value-Baseline value)/Baseline value)*100. ((Week 24 value-Baseline value)/Baseline value)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL at Week 24 of Optional Extension Phase</measure>
    <time_frame>week 24</time_frame>
    <description>Patients maintaining a viral load &lt; 50 copies/mL at week 24 (approximately 168 days) of Optional Extension Phase (OEP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Patients Maintaining a VL &lt; 400 Copies/mL in Optional Extension Phase</measure>
    <time_frame>week 24</time_frame>
    <description>Patients maintaining a viral load &lt; 400 copies/mL at week 24 of the Optional Extension Phase (OEP)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL at Last Available Visit</measure>
    <time_frame>Last available visit, up to 155 weeks</time_frame>
    <description>Patients maintaining a viral load &lt; 50 copies/mL at the last available visit</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Nevirapine IR / Nevirapine XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine Immediate Release (IR)</intervention_name>
    <description>200 mg Tablet or 50 mg / 5 ml oral suspension</description>
    <arm_group_label>Nevirapine IR / Nevirapine XR</arm_group_label>
    <other_name>Nevirapine IR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine Extended Release (XR)</intervention_name>
    <description>200 mg, 300 mg or 400 mg Tablet formulation</description>
    <arm_group_label>Nevirapine IR / Nevirapine XR</arm_group_label>
    <other_name>Nevirapine XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Signed and dated written informed consent of a parent or legal guardian prior to
             admission. Active assent must be given by the patient if the child and/or adolescent
             is capable of understanding the provided study information.

          2. HIV-1 infected males or females &gt;= 3 and &lt; 18 years old.

          3. BSA &gt;= 0.58 m2 for patients using BSA to calculate nevirapine IR dose; or BW &gt;= 12.5
             kg for patients using BW to calculate nevirapine IR dose at screening visit.

          4. Treated with a nevirapine IR based regimen for at least 18 weeks prior to screening
             visit (Visit 1); no modifications in the ARV background therapy within the last 2
             weeks prior to screening.

          5. An HIV VL of &lt;50 copies/mL while receiving nevirapine IR at the last measure of VL
             documented in the medical record obtained within a period of 5 months prior to
             screening visit.

          6. An HIV VL of &lt;50 copies/mL at screening visit.

          7. A stable or not decreasing CD4+ cell count according to the investigator's opinion.

          8. Acceptable screening laboratory values that indicate adequate baseline organ function
             according to the opinion of investigator.

          9. ALT and AST &lt;= 2.5 X ULN (DAIDS Grade 1).

         10. Serum creatinine levels &lt;= 1.3 X ULN (DAIDS Grade 1).

         11. Patients able to swallow tablets.

        Exclusion criteria:

          1. Any AIDS-related or AIDS defining illness that is unresolved or not stable on
             treatment at least 8 weeks prior to screening visit.

          2. Diseases other than HIV infection or conditions that, in the investigator's opinion,
             would interfere with the study.

          3. Patients who have been diagnosed with malignant disease and who are receiving systemic
             chemotherapy or are anticipated to receive any therapy during their participation in
             this trial.

          4. Use of investigational medications or vaccines within 28 days prior to Visit 1 or
             during the trial.

          5. Use of immunomodulatory drugs within 28 days before Visit 1 or during the trial (e.g.,
             interferon, cyclosporin, hydroxyurea, interleukin 2).

          6. Concomitant protease inhibitor (PI) treatment.

          7. Unwillingness to abstain from ingesting substances during the study which may alter
             plasma drug concentrations by interaction with the cytochrome P450 system (Appendix
             10.2).

          8. Female patients of childbearing potential who:

               -  have a positive serum pregnancy test at screening,

               -  are breast feeding,

               -  are planning on becoming pregnant,

               -  are not willing to use double-barrier methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1100.1518.0001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.0002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.2605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Francistown</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.2601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.2603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.4903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.2702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1518.2703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parow Valley</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>Germany</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <results_first_submitted>September 23, 2013</results_first_submitted>
  <results_first_submitted_qc>April 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2014</results_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Multicenter Phase I study in Botswana, Germany, South Africa and the United States.</recruitment_details>
      <pre_assignment_details>There was only one treatment group and no randomization process. Overall, 90 pediatric patients were enrolled. Five patients were not entered and 85 patients entered the study. Patients were stratified to the following three age groups: (26 in the 3 - &lt;6 year age group, 26 in the 6 - &lt; 12 year age group and 33 in the 12 - &lt; 18 year age group).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Total.</title>
          <description>All patients enrolled in study.
All patients initially receive nevirapine immediate release (IR) and then all patients are switched to nevirapine extended release (XR) 100mg or 400mg tablets for a once daily dosing of 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pharmaco-kinetic (PK) Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Optional Extension Phase (OEP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40">Includes only subjects who chose to continue trt with nevirapine XR after completing the PK phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS): All patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Total.</title>
          <description>All patients enrolled in study.
All patients initially receive nevirapine immediate release (IR) and then all patients are switched to nevirapine extended release (XR) 100mg or 400mg tablets for a once daily dosing of 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Cpre,N.</title>
        <description>Trough Nevirapine concentration immediately prior to the next scheduled dose. Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.
The measure of dispersion presented is the coefficient of variation (%) rather than the geometric coefficient of variation.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>PK analysis set (PKS): This patient set includes all patients in the Full Analysis Set (FAS) set that have no protocol violations excluding them from PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Cpre,N.</title>
          <description>Trough Nevirapine concentration immediately prior to the next scheduled dose. Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.
The measure of dispersion presented is the coefficient of variation (%) rather than the geometric coefficient of variation.</description>
          <population>PK analysis set (PKS): This patient set includes all patients in the Full Analysis Set (FAS) set that have no protocol violations excluding them from PK analyses.</population>
          <units>(ng/mL/mg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.47" spread="64.34"/>
                    <measurement group_id="O2" value="16.66" spread="75.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0080</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted geometric means are estimated from the mixed model for intra-individual comparison.</method_desc>
            <param_type>Ratio NVP XR: NVP IR (%)</param_type>
            <param_value>91.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.05</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.47</ci_lower_limit>
            <ci_upper_limit>99.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCt,ss</title>
        <description>Area under the concentration-time curve of the Nevirapine (NVP) in plasma at steady state over the time dosing interval τ.
All patients received nevirapine IR for 10 days prior to collection of 12-hour Area Under the Curve (AUC) data. Then, all patients were switched to nevirapine XR for 9 days prior to collection of 24-hour AUC data. The treatments of IR and XR are summarized separately using geometric means and geometric coefficients of variation.
For NVP IR AUC measured over hours: 0,1,2,3,4,8 and 12, For NVP XR AUC measured over hours: 0,1,2,3,4,8,10,12 and 24.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt,ss</title>
          <description>Area under the concentration-time curve of the Nevirapine (NVP) in plasma at steady state over the time dosing interval τ.
All patients received nevirapine IR for 10 days prior to collection of 12-hour Area Under the Curve (AUC) data. Then, all patients were switched to nevirapine XR for 9 days prior to collection of 24-hour AUC data. The treatments of IR and XR are summarized separately using geometric means and geometric coefficients of variation.
For NVP IR AUC measured over hours: 0,1,2,3,4,8 and 12, For NVP XR AUC measured over hours: 0,1,2,3,4,8,10,12 and 24.</description>
          <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
          <units>ng*h/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200mg NVP XR QD (175-249 mg IR/day), n=23/22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99300" spread="37.7"/>
                    <measurement group_id="O2" value="57900" spread="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300mg NVP XR QD (250-349 mg IR/day), n=11/12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144000" spread="50.1"/>
                    <measurement group_id="O2" value="58100" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400mg NVP XR QD (≥350 mg IR/day), n=11/15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108000" spread="60.7"/>
                    <measurement group_id="O2" value="73400" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmin,ss (for IR and XR Formulations by Nevirapine XR Dose Group)</title>
        <description>Minimum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ by nevirapine XR dose group Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 21.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin,ss (for IR and XR Formulations by Nevirapine XR Dose Group)</title>
          <description>Minimum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ by nevirapine XR dose group Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 21.</description>
          <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 mg XR QD (175-249 mg IR/day), n=23,22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3090" spread="37.9"/>
                    <measurement group_id="O2" value="3280" spread="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg XR QD (250-349 mg IR/day), n=11,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4160" spread="62.6"/>
                    <measurement group_id="O2" value="3620" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400 mg XR QD (≥350 mg IR/day), n=11,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3410" spread="63.0"/>
                    <measurement group_id="O2" value="4960" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss (for IR and XR Formulations by Nevirapine XR Dose Group)</title>
        <description>Maximum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss (for IR and XR Formulations by Nevirapine XR Dose Group)</title>
          <description>Maximum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
          <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 mg XR QD (175-249 mg IR/day), n=23,22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5350" spread="43.1"/>
                    <measurement group_id="O2" value="6850" spread="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg XR QD (250-349 mg IR/day), n=11,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7970" spread="53.5"/>
                    <measurement group_id="O2" value="6580" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400 mg XR QD (≥350 mg IR/day), n=11,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5890" spread="50.5"/>
                    <measurement group_id="O2" value="7790" spread="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio Cmax,ss/Cmin,ss</title>
        <description>Ratio of (maximum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ)/(minimum measured concentration of the analyte in plasma at steady state over the time dosing interval τ) Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio Cmax,ss/Cmin,ss</title>
          <description>Ratio of (maximum measured concentration of the Nevirapine in plasma at steady state over the time dosing interval τ)/(minimum measured concentration of the analyte in plasma at steady state over the time dosing interval τ) Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
          <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 mg XR QD (175-249 mg IR/day), n=23,22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="23.7"/>
                    <measurement group_id="O2" value="2.09" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg XR QD (250-349 mg IR/day), n=11,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="39.4"/>
                    <measurement group_id="O2" value="1.82" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400 mg XR QD (≥350 mg IR/day), n=11,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="21.8"/>
                    <measurement group_id="O2" value="1.57" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>%PTF</title>
        <description>Percentage peak-trough Nevirapine fluctuation, % fluctuation (degree of peak to trough fluctuation) Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>%PTF</title>
          <description>Percentage peak-trough Nevirapine fluctuation, % fluctuation (degree of peak to trough fluctuation) Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
          <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
          <units>percentage fluctuation</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 mg XR QD (175-249 mg IR/day), n=23,22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="47.3"/>
                    <measurement group_id="O2" value="67.9" spread="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg XR QD (250-349 mg IR/day), n=11,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" spread="61.1"/>
                    <measurement group_id="O2" value="59.1" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400 mg XR QD (≥350 mg IR/day), n=11,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="47.6"/>
                    <measurement group_id="O2" value="41.5" spread="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,ss</title>
        <description>Time from dosing to the maximum concentration of the Nevirapine in plasma at steady state over the time dosing interval τ Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.
The standard deviation is actually the coefficient of variation.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,ss</title>
          <description>Time from dosing to the maximum concentration of the Nevirapine in plasma at steady state over the time dosing interval τ Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.
The standard deviation is actually the coefficient of variation.</description>
          <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 mg XR QD (175-249 mg IR/day), n=23,22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.34" spread="104" lower_limit="1.8" upper_limit="24.0"/>
                    <measurement group_id="O2" value="2.46" spread="57.9" lower_limit="0.0" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg XR QD (250-349 mg IR/day), n=11,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.28" spread="121" lower_limit="0.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="2.49" spread="50.4" lower_limit="0.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400 mg XR QD (≥350 mg IR/day), n=11,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="129" lower_limit="0.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="4.41" spread="94.2" lower_limit="0.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F,ss</title>
        <description>Apparent clearance of the Nevirapine in the plasma after extravascular administration at steady-state Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F,ss</title>
          <description>Apparent clearance of the Nevirapine in the plasma after extravascular administration at steady-state Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
          <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
          <units>mL/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 mg XR QD (175-249 mg IR/day), n=23,22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2010" spread="37.7"/>
                    <measurement group_id="O2" value="1780" spread="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg XR QD (250-349 mg IR/day), n=11,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2080" spread="50.1"/>
                    <measurement group_id="O2" value="2240" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400 mg XR QD (≥350 mg IR/day), n=11,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3700" spread="60.7"/>
                    <measurement group_id="O2" value="2640" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cavg</title>
        <description>Average measured concentration of the Nevirapine in plasma at steady state Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
        <time_frame>Day 11 prior to the next scheduled dose of Nevirapine IR and day 22 prior to the next scheduled dose of Nevirapine XR</time_frame>
        <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP XR</title>
            <description>Nevirapine XR (extended release)</description>
          </group>
          <group group_id="O2">
            <title>NVP IR</title>
            <description>Nevirapine IR (immediate release)</description>
          </group>
        </group_list>
        <measure>
          <title>Cavg</title>
          <description>Average measured concentration of the Nevirapine in plasma at steady state Patients took Nevirapine (NVP) Immediate Release (IR) up to day 10 and had PK measurements taken on Day 11. This was followed by 9 days (from day 12 to day 20) taking NVP Extended Release (XR) with PK measurements taken on Day 22.</description>
          <population>Intensive PK analysis set (IPK): This patient set includes all patients in the PK set that underwent intensive PK sampling.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>200 mg XR QD (175-249 mg IR/day), n=23,22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4140" spread="37.7"/>
                    <measurement group_id="O2" value="4820" spread="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg XR QD (250-349 mg IR/day), n=11,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6010" spread="50.1"/>
                    <measurement group_id="O2" value="4840" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>400 mg XR QD (≥350 mg IR/day), n=11,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4510" spread="60.7"/>
                    <measurement group_id="O2" value="6120" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL</title>
        <description>Patients maintaining a viral load &lt; 50 copies/mL at Day 22.</description>
        <time_frame>Day 22</time_frame>
        <population>Full analysis set including patients with available viral load data at day 22</population>
        <group_list>
          <group group_id="O1">
            <title>3-&lt;6 yr</title>
            <description>Patients 3 to &lt; 6 years old.</description>
          </group>
          <group group_id="O2">
            <title>6-&lt;12 yr</title>
            <description>Patients 6 to &lt; 12 years old.</description>
          </group>
          <group group_id="O3">
            <title>12-&lt;18 yr</title>
            <description>Patients 12 to &lt; 18 years old.</description>
          </group>
          <group group_id="O4">
            <title>Total.</title>
            <description>All patients initially receive nevirapine immediate release (IR) and then all patients are switched to nevirapine extended release (XR) 100mg or 400mg tablets for a once daily dosing of 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL</title>
          <description>Patients maintaining a viral load &lt; 50 copies/mL at Day 22.</description>
          <population>Full analysis set including patients with available viral load data at day 22</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Patients Maintaining a VL &lt; 400 Copies/mL</title>
        <description>Patients maintaining a viral load &lt; 400 copies/mL at Day 22</description>
        <time_frame>Day 22</time_frame>
        <population>Full analysis set including patients with available viral load data at day 22</population>
        <group_list>
          <group group_id="O1">
            <title>3-&lt;6 yr</title>
            <description>Patients 3 to &lt; 6 years old.</description>
          </group>
          <group group_id="O2">
            <title>6-&lt;12 yr</title>
            <description>Patients 6 to &lt; 12 years old.</description>
          </group>
          <group group_id="O3">
            <title>12-&lt;18 yr</title>
            <description>Patients 12 to &lt; 18 years old.</description>
          </group>
          <group group_id="O4">
            <title>Total.</title>
            <description>All patients initially receive nevirapine immediate release (IR) and then all patients are switched to nevirapine extended release (XR) 100mg or 400mg tablets for a once daily dosing of 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Patients Maintaining a VL &lt; 400 Copies/mL</title>
          <description>Patients maintaining a viral load &lt; 400 copies/mL at Day 22</description>
          <population>Full analysis set including patients with available viral load data at day 22</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean CD4+ Count (Absolute)</title>
        <description>Change in mean CD4+ count (absolute) from baseline to Day 22 and from baseline to Week 24.</description>
        <time_frame>Baseline, Day 22 and week 24</time_frame>
        <population>PK Analysis set: This patient set includes all patients in the Full Analysis Set (FAS) that have no protocol violations excluding them from PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>3-&lt;6 yr</title>
            <description>Patients 3 to &lt; 6 years old.</description>
          </group>
          <group group_id="O2">
            <title>6-&lt;12 yr</title>
            <description>Patients 6 to &lt; 12 years old.</description>
          </group>
          <group group_id="O3">
            <title>12-&lt;18 yr</title>
            <description>Patients 12 to &lt; 18 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean CD4+ Count (Absolute)</title>
          <description>Change in mean CD4+ count (absolute) from baseline to Day 22 and from baseline to Week 24.</description>
          <population>PK Analysis set: This patient set includes all patients in the Full Analysis Set (FAS) that have no protocol violations excluding them from PK analysis.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-115.6" spread="320.5"/>
                    <measurement group_id="O2" value="24.2" spread="184.8"/>
                    <measurement group_id="O3" value="60.3" spread="171.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=8;10;9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-214.5" spread="397.5"/>
                    <measurement group_id="O2" value="-51.2" spread="179.4"/>
                    <measurement group_id="O3" value="31.1" spread="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Mean CD4+ Count</title>
        <description>((Day 22 value-Baseline value)/Baseline value)*100. ((Week 24 value-Baseline value)/Baseline value)*100.</description>
        <time_frame>Baseline to day 22 and baseline to week 24</time_frame>
        <population>Optional Extension Phase Treated Set (OEP TS), all patients that complete PK phase and enroll in Extension phase, and had available data at either day 22 or week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>3-&lt;6 yr</title>
            <description>Patients 3 to &lt; 6 years old.</description>
          </group>
          <group group_id="O2">
            <title>6-&lt;12 yr</title>
            <description>Patients 6 to &lt; 12 years old.</description>
          </group>
          <group group_id="O3">
            <title>12-&lt;18 yr</title>
            <description>Patients 12 to &lt; 18 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Mean CD4+ Count</title>
          <description>((Day 22 value-Baseline value)/Baseline value)*100. ((Week 24 value-Baseline value)/Baseline value)*100.</description>
          <population>Optional Extension Phase Treated Set (OEP TS), all patients that complete PK phase and enroll in Extension phase, and had available data at either day 22 or week 24.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="6.7"/>
                    <measurement group_id="O2" value="-0.0" spread="2.5"/>
                    <measurement group_id="O3" value="0.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=8, 10, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="4.0"/>
                    <measurement group_id="O2" value="-2.1" spread="3.4"/>
                    <measurement group_id="O3" value="-1.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL at Week 24 of Optional Extension Phase</title>
        <description>Patients maintaining a viral load &lt; 50 copies/mL at week 24 (approximately 168 days) of Optional Extension Phase (OEP).</description>
        <time_frame>week 24</time_frame>
        <population>Full analysis set including patients with available viral load data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>3-&lt;6 yr</title>
            <description>Patients 3 to &lt; 6 years old.</description>
          </group>
          <group group_id="O2">
            <title>6-&lt;12 yr</title>
            <description>Patients 6 to &lt; 12 years old.</description>
          </group>
          <group group_id="O3">
            <title>12-&lt;18 yr</title>
            <description>Patients 12 to &lt; 18 years old.</description>
          </group>
          <group group_id="O4">
            <title>Total.</title>
            <description>All patients initially receive nevirapine immediate release (IR) and then all patients are switched to nevirapine extended release (XR) 100mg or 400mg tablets for a once daily dosing of 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL at Week 24 of Optional Extension Phase</title>
          <description>Patients maintaining a viral load &lt; 50 copies/mL at week 24 (approximately 168 days) of Optional Extension Phase (OEP).</description>
          <population>Full analysis set including patients with available viral load data at week 24</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Patients Maintaining a VL &lt; 400 Copies/mL in Optional Extension Phase</title>
        <description>Patients maintaining a viral load &lt; 400 copies/mL at week 24 of the Optional Extension Phase (OEP)</description>
        <time_frame>week 24</time_frame>
        <population>Full analysis set including patients with available viral load data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>3-&lt;6 yr</title>
            <description>Patients 3 to &lt; 6 years old.</description>
          </group>
          <group group_id="O2">
            <title>6-&lt;12 yr</title>
            <description>Patients 6 to &lt; 12 years old.</description>
          </group>
          <group group_id="O3">
            <title>12-&lt;18 yr</title>
            <description>Patients 12 to &lt; 18 years old.</description>
          </group>
          <group group_id="O4">
            <title>Total.</title>
            <description>All patients initially receive nevirapine immediate release (IR) and then all patients are switched to nevirapine extended release (XR) 100mg or 400mg tablets for a once daily dosing of 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Patients Maintaining a VL &lt; 400 Copies/mL in Optional Extension Phase</title>
          <description>Patients maintaining a viral load &lt; 400 copies/mL at week 24 of the Optional Extension Phase (OEP)</description>
          <population>Full analysis set including patients with available viral load data at week 24</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL at Last Available Visit</title>
        <description>Patients maintaining a viral load &lt; 50 copies/mL at the last available visit</description>
        <time_frame>Last available visit, up to 155 weeks</time_frame>
        <population>Optional Extension Phase Treated Set (OEP TS), all patients that complete PK phase and enroll in Extension phase with VL data available</population>
        <group_list>
          <group group_id="O1">
            <title>3-&lt;6 yr</title>
            <description>Patients 3 to &lt; 6 years old.</description>
          </group>
          <group group_id="O2">
            <title>6-&lt;12 yr</title>
            <description>Patients 6 to &lt; 12 years old.</description>
          </group>
          <group group_id="O3">
            <title>12-&lt;18 yr</title>
            <description>Patients 12 to &lt; 18 years old.</description>
          </group>
          <group group_id="O4">
            <title>Total.</title>
            <description>All patients initially receive nevirapine immediate release (IR) and then all patients are switched to nevirapine extended release (XR) 100mg or 400mg tablets for a once daily dosing of 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Patients Maintaining a VL &lt; 50 Copies/mL at Last Available Visit</title>
          <description>Patients maintaining a viral load &lt; 50 copies/mL at the last available visit</description>
          <population>Optional Extension Phase Treated Set (OEP TS), all patients that complete PK phase and enroll in Extension phase with VL data available</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first drug administration until 14 days after the last drug administration, up to 157 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Total.</title>
          <description>All patients enrolled in study.
All patients initially receive nevirapine immediate release (IR) and then all patients are switched to nevirapine extended release (XR) 100mg or 400mg tablets for a once daily dosing of 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

